Phase 1 (ASH Data Presentation)
Dec 5-8, 2020
Amp Volatility Score
Catalyst Info & Data Links
TITLE: APTO-253 in RR Acute Myelogenous Leukemia/ HR Myelodysplasia
ClinicalTrial.gov (NCT02267863): A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
12-29-2016 Provides Update on APTO-253 Development
10-13-2016 Update on FDA Clinical Hold of APTO-253
12-2019: Aptose Corporate Update: Early Clinical Observations APTO-253 (slide 33-36)
04-2020: Aptose Corporate Presentation (slide 24-28)
~13K MDS incidence per year in the U.S.
~30% of MDS cases progress to AML
~35.7K prevalence for AML
~18.8K Patients with new AML diagnoses
MECHANSIM OF ACTION/RATIONALE
APTO-253 as a Small Molecular MYC Inhibitor: APTO-253 does not target directly the MYC protein, but rather binds directly and selectively to a regulatory motif in the promoter of the MYC oncogene and dramatically down-regulates expression of the MYC protein in tumor cells, leading to apoptotic cell death. Thus, APTO-253 may serve as a safe and effective MYC inhibitor for MYC-driven or MYC-dependent tumors that combines well with other anti-tumor agents.
Updated by HC
APTO, APTO-253, acute_myeloid_leukemia, myelodysplastic_syndrome, ASH, ASH2020
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post